Sulfasalazine-Induced Pancytopenia in Ulcerative Colitis

Authors

  • NS Neki Professor, Department of Medicine, Government Medical College/Guru Nanak Dev Hospital, Amritsar
  • Ankur Jain Junior Resident, Department of Medicine, Government Medical College/Guru Nanak Dev Hospital, Amritsar

DOI:

https://doi.org/10.3329/jemc.v6i3.29685

Keywords:

Sulfasalazine, Ulcerative colitis, Pancytopenia, Myelosuppression

Abstract

Sulfasalazine is a well-established disease-modifying agent. It is commonly used in the treatment of rheumatic disorders and inflammatory bowel disease. The most frequently reported adverse effects are gastrointestinal effects, headache, dizziness and rash; myelosuppression can also occur. Patients treated with sulfasalazine can develop thrombocytopenia which is immune mediated. We report a case of ulcerative colitis that was on sulfasalazine subsequently developing thrombocytopenia.

J Enam Med Col 2016; 6(3): 164-165

Downloads

Download data is not yet available.
Abstract
1031
PDF
752

Author Biography

NS Neki, Professor, Department of Medicine, Government Medical College/Guru Nanak Dev Hospital, Amritsar



Downloads

Published

2016-10-20

How to Cite

Neki, N., & Jain, A. (2016). Sulfasalazine-Induced Pancytopenia in Ulcerative Colitis. Journal of Enam Medical College, 6(3), 164–165. https://doi.org/10.3329/jemc.v6i3.29685

Issue

Vol. 6 No. 3 (2016)

Section

Case Reports

License

  • Copyright on any research article is transferred in full to Journal of Enam Medical College upon publication in the journal. The copyright transfer includes the right to reproduce and distribute the article in any form of reproduction (printing, electronic media or any other form).
  • Articles in the Journal of Enam Medical College are Open Access articles published under the Creative Commons CC BY License (https://creativecommons.org/licenses/by/4.0/)
  • This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.